Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLH and tetanus co-immunization immune response study in healthy volunteers
NL-OMON45727Phase 4Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Mar 2017
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of IMG KLH, aluminium hydroxide and tetanus toxoid (3 arms), sponsored by Centre for Human Drug Research. Primary endpoints: KLH-specific IgG and IgM titers, Tetanus toxoid-specific IgG and IgM titers and 10 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
IMG KLHaluminium hydroxidetetanus toxoid
Beyond the preview
Go deeper on NL-OMON45727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45727.